Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA). Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated. Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate. Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2-3.2, p = 0.005). Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.

Effectiveness of adalimumab for the treatment of psoriatic arthritis: An Italian real-life retrospective study / D'Angelo, S.; Cantini, F.; Ramonda, R.; Cantarini, L.; Carletto, A.; Chimenti, M. S.; Sedie, A. D.; Foti, R.; Gerli, R.; Lomater, C.; Lubrano, E.; Marchesoni, A.; Zabotti, A.; Salvarani, C.; Scrivo, R.; Scarpa, R.; Tramontano, G.; Nannini, C.; Lorenzin, M.; Fabbroni, M.; Martinis, F.; Perricone, R.; Carli, L.; Visalli, E.; Rovera, G.; Perrotta, F. M.; Quartuccio, L.; Altobelli, A.; Costa, L.; Niccoli, L.; Ortolan, A.; Caso, F.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 10:(2019), pp. 1497-1497. [10.3389/fphar.2019.01497]

Effectiveness of adalimumab for the treatment of psoriatic arthritis: An Italian real-life retrospective study

Salvarani C.;
2019

Abstract

Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA). Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated. Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate. Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2-3.2, p = 0.005). Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.
2019
10
1497
1497
Effectiveness of adalimumab for the treatment of psoriatic arthritis: An Italian real-life retrospective study / D'Angelo, S.; Cantini, F.; Ramonda, R.; Cantarini, L.; Carletto, A.; Chimenti, M. S.; Sedie, A. D.; Foti, R.; Gerli, R.; Lomater, C.; Lubrano, E.; Marchesoni, A.; Zabotti, A.; Salvarani, C.; Scrivo, R.; Scarpa, R.; Tramontano, G.; Nannini, C.; Lorenzin, M.; Fabbroni, M.; Martinis, F.; Perricone, R.; Carli, L.; Visalli, E.; Rovera, G.; Perrotta, F. M.; Quartuccio, L.; Altobelli, A.; Costa, L.; Niccoli, L.; Ortolan, A.; Caso, F.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 10:(2019), pp. 1497-1497. [10.3389/fphar.2019.01497]
D'Angelo, S.; Cantini, F.; Ramonda, R.; Cantarini, L.; Carletto, A.; Chimenti, M. S.; Sedie, A. D.; Foti, R.; Gerli, R.; Lomater, C.; Lubrano, E.; Marchesoni, A.; Zabotti, A.; Salvarani, C.; Scrivo, R.; Scarpa, R.; Tramontano, G.; Nannini, C.; Lorenzin, M.; Fabbroni, M.; Martinis, F.; Perricone, R.; Carli, L.; Visalli, E.; Rovera, G.; Perrotta, F. M.; Quartuccio, L.; Altobelli, A.; Costa, L.; Niccoli, L.; Ortolan, A.; Caso, F.
File in questo prodotto:
File Dimensione Formato  
fphar-10-01497.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 455.95 kB
Formato Adobe PDF
455.95 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1193778
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact